PDCD1 and small cell lung carcinoma: Notably, serplulimab, the sole PD-1 inhibitor approved for ES-SCLC, manifested an OS of 15.8 months—translating into a marked survival elongation of 4.7 months vis-a-vis standard chemotherapy and a consequential 38% reduction in mortality risk.